RETRACTION

## FOXN4 Inhibits Breast Cancer Progression by Direct Activation of P53 [Retraction]

Ye H, Duan M. Onco Targets Ther. 2020;13:71—81.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article.

The journal was notified of similarities between the published paper and another article published in the journal *Gene*:

 Identification of FOXN4 as a tumor suppressor of breast carcinogenesis via the activation of TP53 and deactivation of Notch signaling (<a href="https://doi.org/10.1016/j.gene.2019.144057">https://doi.org/10.1016/j.gene.2019.144057</a>).

In particular, it was noted both articles presented similar data in Table 1 and shared nearly identical reference lists.

The article was submitted and accepted by *OncoTargets* and *Therapy* prior to publication in *Gene*, however it was noted the article was submitted to *Gene* prior to publication in *OncoTargets and Therapy*.

The authors were unable to provide a satisfactory explanation for the similarities and were also unable to provide satisfactory raw data for the study.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal



